These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21811996)

  • 1. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus.
    Mathian A; Devilliers H; Krivine A; Costedoat-Chalumeau N; Haroche J; Huong DB; Wechsler B; Hervier B; Miyara M; Morel N; Le Corre N; Arnaud L; Piette JC; Musset L; Autran B; Rozenberg F; Amoura Z
    Arthritis Rheum; 2011 Nov; 63(11):3502-11. PubMed ID: 21811996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus.
    Campos LM; Silva CA; Aikawa NE; Jesus AA; Moraes JC; Miraglia J; Ishida MA; Bueno C; Pereira RM; Bonfa E
    Arthritis Care Res (Hoboken); 2013 Jul; 65(7):1121-7. PubMed ID: 23818263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases.
    Elkayam O; Amir S; Mendelson E; Schwaber M; Grotto I; Wollman J; Arad U; Brill A; Paran D; Levartovsky D; Wigler I; Caspi D; Mandelboim M
    Arthritis Care Res (Hoboken); 2011 Jul; 63(7):1062-7. PubMed ID: 21425247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?
    Borba EF; Saad CG; Pasoto SG; Calich AL; Aikawa NE; Ribeiro AC; Moraes JC; Leon EP; Costa LP; Guedes LK; Silva CA; Goncalves CR; Fuller R; Oliveira SA; Ishida MA; Precioso AR; Bonfa E
    Rheumatology (Oxford); 2012 Jun; 51(6):1061-9. PubMed ID: 22298793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminished immunogenicity to pandemic H1N1 2009 influenza vaccine in subjects with severe motor and intellectual disability.
    Hara M; Hanaoka T; Mizushima T; Honma J; Maeda K; Ohfuji S; Tanaka K; Hirota Y
    Vaccine; 2011 Oct; 29(46):8323-9. PubMed ID: 21893146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children.
    Block SL; Ruiz-Palacios GM; Guerrero ML; Beygo J; Sales V; Holmes SJ
    Pediatr Infect Dis J; 2012 Jul; 31(7):e92-8. PubMed ID: 22481427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study.
    Holvast A; van Assen S; de Haan A; Huckriede A; Benne CA; Westra J; Palache A; Wilschut J; Kallenberg CG; Bijl M
    Rheumatology (Oxford); 2009 Oct; 48(10):1294-9. PubMed ID: 19692457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
    Hakim H; Allison KJ; Van De Velde LA; Li Y; Flynn PM; McCullers JA
    Vaccine; 2012 Jan; 30(5):879-85. PubMed ID: 22155630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients.
    Lertdumrongluk P; Changsirikulchai S; Limkunakul C; Prachukthum P; Punpiput P; Buppanharun R; Chotpitayasunondh C
    Vaccine; 2012 Feb; 30(6):1108-14. PubMed ID: 22178515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.
    Cullen G; Bader C; Korzenik JR; Sands BE
    Gut; 2012 Mar; 61(3):385-91. PubMed ID: 21757451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
    Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus.
    Urowitz MB; Anton A; Ibanez D; Gladman DD
    Arthritis Care Res (Hoboken); 2011 Nov; 63(11):1517-20. PubMed ID: 22034113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial.
    Tsatsaris V; Capitant C; Schmitz T; Chazallon C; Bulifon S; Riethmuller D; Picone O; Poulain P; Lewin F; Lainé F; Jacqz-Aigrain E; Aboulker JP; Launay O;
    Ann Intern Med; 2011 Dec; 155(11):733-41. PubMed ID: 22147712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation.
    Lagler H; Tobudic S; Ramharter M; Elandt K; Sperr WR; Redlberger-Fritz M; Popow-Kraupp T; Jäger U; Zielinski CC; Burgmann H
    Vaccine; 2012 Nov; 30(48):6864-70. PubMed ID: 22989690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Safety of Influenza Vaccination in Systemic Lupus Erythematosus Patients Compared with Healthy Controls: A Meta-Analysis.
    Liao Z; Tang H; Xu X; Liang Y; Xiong Y; Ni J
    PLoS One; 2016; 11(2):e0147856. PubMed ID: 26845680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.
    Le Corre N; Thibault F; Pouteil Noble C; Meiffrédy V; Daoud S; Cahen R; Charreau I; Bottigioli D; Dollinger C; Aboulker JP; Autran B; Morelon E; Barrou B
    Vaccine; 2012 Dec; 30(52):7522-8. PubMed ID: 23103195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus.
    Holvast A; van Assen S; de Haan A; Huckriede A; Benne CA; Westra J; Palache A; Wilschut J; Kallenberg CG; Bijl M
    Arthritis Rheum; 2009 Aug; 60(8):2438-47. PubMed ID: 19644961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to a monovalent 2009 influenza A (H1N1) vaccine.
    Greenberg ME; Lai MH; Hartel GF; Wichems CH; Gittleson C; Bennet J; Dawson G; Hu W; Leggio C; Washington D; Basser RL
    N Engl J Med; 2009 Dec; 361(25):2405-13. PubMed ID: 19745216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients.
    Salles MJ; Sens YA; Malafronte P; Souza JF; Vilas Boas LS; Machado CM
    Transpl Infect Dis; 2012 Dec; 14(6):564-74. PubMed ID: 22882692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.